A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
Status:
Unknown status
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to evaluate the
efficacy and safety of SP2086 in combination therapy with Metformin in patients with Type 2
Diabetes Mellitus in Metformin monotherapy Who Have Inadequate Glycemic Control